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Introduction
Chelidonium majus L. (CM), also known as 
greater celandine, is a plant of the family Pa-
paveraceae, which grows wild in part of Asia, 
Central and Southern Europe, in the Azores 
and North America1,2. It has been used for 
a long time in hepatobiliary disorders: gall 
bladder and digestive dysfunctions; dyspeptic 
complaints and spasms in phytotherapy and 
traditional medicine3. Currently, CM is widely 
marketed on the websites of natural products as 
a remedy against several medical complaints. 
The plant contains quaternary and tertiary ben-
zo[c]phenanthridine alkaloids as major active 
components4. Recently, numerous hepatotoxici-
ty reports have been suggested as linked with 
the use of herbal supplements containing CM5,6. 
However, the causal relationship between CM 
intake and the occurrence of liver damage has 
not yet been fully established7. Animal studies 
showed that the prolonged administration of 
high doses of CM to rats did not determine liver 
damage, leading the authors to suggest to exclu-
de an intrinsic plant toxicity8. Hence, it has been 
hypothesized that the harmfulness could have 
been due to pharmacological interaction9-12. In 
this concern, the most severe reactions have 
been observed in subjects undergoing simulta-
neous treatment with CM and hormones (estro-
gens, thyroid hormones) and/or non-steroidal 
anti-inflammatory drugs (NSAIDs)13. The aim 
of this paper was to review the available litera-
ture assessing CM characteristics, risk to bene-
fit ratio and its hepatotoxicity potential.
Abstract. – The available literature assessing 
Chelidonium majus L. (CM) hepatotoxicity poten-
tial, and its risk to benefit assessment has been 
reviewed in this paper. Identification of signifi-
cant scientific literature was performed via the 
following research databases: Cochrane Cen-
tral, Google Scholar, EMBASE, Medline, Science 
Direct, Scopus, Web of Science, using the fol-
lowing keywords: “Chelidonium majus”, “great-
er celandine”, “Hepatotoxicity”, “Liver” “Inju-
ry”, “Toxicity” individually investigated and then 
again in association. CM named also greater cel-
andine, swallow-wort, or bai-qu-cai (Chinese), 
has been used for a long time in traditional Chi-
nese medicine and phytotherapy. Its extracts 
have been claimed to display a wide variety of bi-
ological activities: antimicrobial, anti-inflamma-
tory, spasmolytic, antineoplastic, hepatoprotec-
tive, and analgesic. Moreover, herbal medicine 
suggests this plant have numerous addition-
al effects which have not yet been scientifical-
ly evaluated, such as antitussive, diuretic, and 
eye-regenerative. However, despite its claimed 
hepatoprotective effects, several hepatotoxici-
ty cases have been reported to be probably or 
highly probably connected with CM exposure, 
after their evaluation through liver-targeted cau-
sality assessment methods. CM hepatotoxicity 
has been defined as a distinct form of herb-in-
duced liver injury (HILI), due to an idiosyncrat-
ic reaction of the metabolic type. This evidence 
has to be considered in relationship with the 
absence of considerable benefits of CM thera-
py. Therefore, the risk to benefit ratio of the use 
of herbal products containing greater celandine 
can actually be considered as negative.
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Materials and Methods 
The selection of appropriate scientific articles 
was performed through the following research 
engines: Cochrane Central, Google Scholar, EM-
BASE, Medline, Science Direct, Scopus, Web of 
Science, up to October 2016 using the following 
keywords: “Chelidonium majus”, “greater celan-
dine”, “Hepatotoxicity”, “Liver” “Injury”, “Toxi-
city”. The main keywords “Chelidonium majus” 
and “greater celandine” were searched individual-
ly and then in association with each of the others. 
The 244 and 57 sources initially found respecti-
vely with “Chelidonium majus” and “greater ce-
landine”, were screened to exclude papers not su-
itable for the purpose of the review and duplicate 
sources. Only 43 papers [1, 4, 7-8, 10, 13-50] (25 
research articles, 8 case reports, 9 reviews and 1 
book) were included in the results. Moreover, a 
hand search was performed through the referen-
ces of the identified articles.
Results
CM Mechanism of Action
A huge number of studies have been develo-
ped to assess CM efficacy in a large number of 
conditions, as this plant has been claimed to pro-
duce a wide variety of pharmacological effects1. 
Medicinal properties of CM can be attributed to 
the isoquinoline alkaloids contained in the plant 
(root and aerial part). More than 27 components 
have been described and divided into three main 
groups: a) benzo[c]phenanthridines, among which 
there are two subgroups -quaternary (chelerythri-
ne and sanguinarine) and -tertiary like chelidoni-
ne; b) protopine and derivatives such as allocryp-
topine; c) protoberberines (berberine, coptisine)4. 
The plant contains flavonoids and phenolic acids 
as well14. 
Anticancer activity of CM has been observed 
in vitro studies. The plant constituents determine 
cancer cell apoptosis and inhibition of mitosis15-17. 
Specifically, Ukrain, a semi-synthetic alkaloid 
derived from CM, is characterized by antitumor, 
antineoplastic and immunomodulatory proper-
ties, determining dose and time dependent cyto-
toxicity on cancer cell lines, among which those 
of breast cancer18,19. Moreover, these effects have 
been observed after the administration of the 
whole extract of CM20. Ukrain, showed therapeu-
tic effects with low adverse reactions on various 
kinds of cancer (colorectal, breast, pancreatic, 
bladder) and on Kaposi’s sarcoma, as highlighted 
by human clinical studies21. 
Also, CM action against inflammation has 
been studied in animal models, demonstrating 
that the methanol extract of this plant was able 
to inhibit the evolution of collagen-induced ar-
thritis in mice, decreasing the synthesis of certain 
cytokines and modulating the amount of immune 
cells and immunoglobulins22. Kokoska and colle-
agues suggested that this herb could be one of the 
most active as an antimicrobial agent23. Choleretic 
activity has been studied on isolated perfused rat 
livers, on which alkaloid and phenolic fractions 
derived from CM and CM extract, determined 
a doubling of the amount of produced bile and a 
reduction of bile acid concentration, after 40 mi-
nutes24. The choleretic effect has also been stu-
died in humans, through the administration of a 
hydroethanolic extract intragastrically in healthy 
patients and in subjects suffering from liver il-
lness. Bile flow was found to be increased25. Liver 
protection has been studied on rats, evaluating 
the defense from the toxicity due to carbon tetra-
chloride, through the administration of a whole 
extract of CM in ethanol26,27. It has been shown 
that the previous treatment with CM was able to 
reduce the number of necrotic cells, the value of 
transaminases, bilirubin, and the fibrotic changes 
due to carbon tetrachloride exposure. Also, the 
hepatocarcinogenesis caused by p-dimethylami-
noazobenzene was found to be antagonized by 
CM in mice28. Anti-ulcerogenic and gastropro-
tective effects of CM extract have been evaluated 
on gastric ulcers induced by indomethacin in rats. 
CM showed an action against the development of 
ulcers, enhancing the release of prostaglandin E2 
and decreasing leukotrienes29, and producing an 
antispasmodic and analgesic activity as well. The 
analgesic effect determined by its alkaloids was 
similar to that of morphine. The CM extracts pro-
duced a relaxing and spasmolytic action on the 
abdominal and gastrointestinal muscles in animal 
models, being able to reduce pain30,32. This effect 
was observed also in human clinical studies33.
CM Hepatotoxicity
Animal Studies
Some studies on animal models have been de-
veloped in order to assess the defensive proper-
ties of CM constituents or their ability to enhance 
the toxicity of other molecules. The protective 
potential of chelidonine, the major active compo-
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nent of Chelidonium majus, and of its poly lacti-
de-co-glycolide (PLGA) poly incapsulated nano-
form (nano-chelidonine), has been evaluated in 
the oxidative stress and hepatic toxicity induced 
by cadmium chloride (CdCl2) in mice
34. The study 
results showed that the exposure to CdCl2 for 30 
days (twice a week at the following dosage: 1.0 
mg/kg body weight i.p.) caused oxidative stress 
through lipid peroxidation and accumulation of re-
active oxygen species (ROS). The administration 
of nano-chelidonine after CdCl2 exposure mar-
kedly diminished lipid peroxidation and oxidati-
ve stress and restored GSH (glutathione) levels. 
Therefore, nano-chelidonine was suggested as a 
protective agent, in mice, against cadmium toxici-
ty. Also, the ability of CM to enhance the hepatic 
effects of acetaminophen at a sub-toxic dose was 
evaluated in rats7. If administered alone, CM did 
not modify liver parameters in male rats while in 
female animals a rise of fibrinogen levels was ob-
served. No changes in hepatic histomorphology 
were noticed in both sexes. Liver alterations were 
observed after the administration of sub-toxic do-
ses of acetaminophen, while the co-administra-
tion of CM did not enhance hepatotoxic effects. 
Additionally, the anti-tumor properties of CM 
and its modulation of enzyme activity in the liver 
have been studied administering a homeopathic 
extract (in micro doses Ch-30 and Ch-200) of CM 
to mice, during hepatocarcinogenesis induced by 
p-DAB (p-dimethylaminoazobenzene) compared 
to control groups35. All mice that were admini-
stered p-DAB developed liver tumors. Approxi-
mately the 40% of the animals in which p-DAB 
was administered in association with Chelido-
nium, did not develop liver tumors. Chelidonium 
homeopathic medicine showed an anti-tumor ef-
fect and an anti-genotoxic activity and favorably 
modulated the effects of certain enzyme markers. 
Moreover, the inhibition potency of CM alkaloids 
on several enzymes was tested in animal stu-
dies. Chelidonine, berberine, sanguinarine, and 
“Ukrain” (a semisynthetic drug derived from CM) 
displayed an irreversible inhibition of serotonin 
and tyramine oxidative deamination reaction, 
in rat livers mitochondrial monoamine oxidase 
(MAO)36. However, the same metabolic pathway 
was not blocked for the substrate benzylamine. 
This finding suggests that mainly oxidative dea-
mination performed by MAO form A is blocked 
by CM alkaloids. Ukrain and chelidonine showed 
the strongest inhibition potency, while sanguina-
rine and berberine exhibited a weaker action37. Si-
milarly, the inhibition potential of CM alkaloids, 
was studied in liver mitochondria of male albino 
mice4. The molecules showing greater inhibition 
strength in mitochondrial respiration were tho-
se containing a positive charge, for the presence 
in their structure of a quaternary nitrogen atom: 
chelerythrine, sanguinarine, berberine and copti-
sine. The uncharged CM constituents underwent 
more troubles in passing through the mitochon-
drial membrane. Berberine, was the most biologi-
cally active alkaloid tested, and for this reason, it 
should display the highest toxicity. Moreover, the 
effects of chelidonine, coptisine, chelerythrine, 
and sanguinarine were studied on oxidative pho-
sphorylation and calcium accumulation in rat li-
ver mitochondria38. Chelerythrine and sanguina-
rine determined a block of the absorption and the 
accumulation of calcium cations and repressed 
oxidative phosphorylation, while chelidonine did 
not influence the studied parameters. The effects 
observed on mitochondria are directly connected 
to DNA intercalating properties, as sanguinarine 
and chelerythrine are strong intercalators, while 
chelidonine is not. Finally, after oral administra-
tion of CM on Wistar rats for two or four weeks, 
at the following dosage: 1.5-3 g/(kg day) (this 
amount should be considered 50-100 times higher 
than that generally consumed by humans), no sub-
stantial change was noticed in animals, regarding 
to: body weight, food intake, enzyme activities 
and liver histomorphology. Nevertheless, a mild 
but significant reduction of GSH levels, as well as 
superoxide dismutase (SOD) activity was obser-
ved. Therefore, these mild alterations suggest par-
ticular caution in administering CM in conditions 
characterized by an impairment of liver function8. 
Human Hepatotoxicity Reports 
The liver damage due to herbal remedies is also 
named: herb-induced liver injury (HILI). The lat-
ter represents a rare occurrence that follows the 
exposure in a small amount of susceptible indivi-
duals39-41. HILI features are comparable to those 
of drug-induced liver injury (DILI). While per-
forming causality assessment, it is of primary im-
portance to choose the proper evaluation method. 
Teschke and Danan stressed the concept that cau-
sality assessment in HILI suspected cases should 
be performed through the Council for International 
Organizations of Medical Sciences scale (CIOMS), 
also known as Roussel Uclaf Causality Assessment 
Method (RUCAM) which is an instrument valida-
ted for hepatotoxicity and specific for the liver42. 
Liver damage due to CM intake in humans 
has been mainly supported by case reports and 
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reviews that evaluated the cases reported in 
scientific papers and spontaneous signaled ad-
verse reactions. The onset of haemolytic anae-
mia due to the oral ingestion of CM extract was 
firstly observed in 1990 and was characterized 
by intravascular haemolysis, thrombocytope-
nia, renal failure and liver cytolysis43. The pa-
tient underwent treatment with steroids, blood 
components, transfusion and with haemodialy-
sis twice. The 12th-day complete resolution of 
the clinical features was observed. Similarly, a 
42-year-old woman was admitted to the hospital 
because of the reappearance of acute hepatitis of 
uncertain origin44. Her past clinical history was 
characterized by alanine transaminase (ALT) 
elevation (concentration of 755 U/l), preceded 
by the intake of herbal remedies as an alterna-
tive medication, including common (or lesser) 
celandine. ALT maximum values during the 
hospitalization were 350 U/l. All other possible 
causes of hepatitis, such as viral infection, meta-
bolic diseases, and autoimmune aetiology were 
excluded. Liver biopsy showed an acute necroti-
zing hepatitis. Treatment was performed mainly 
through the avoidance of re-exposure and liver 
enzymes returned normal. Concordantly, ten 
cases of acute hepatitis connected with the in-
take of CM preparations were noticed from 
1997 until 1999 in Germany13. The evolution of 
liver impairment in these patients was mild to 
severe. In half of the cases, important cholesta-
sis was detected, but was not followed by liver 
failure. Other potential sources of liver dama-
ge such as secondary biliary, alcoholic dama-
ge, viral hepatitis, hereditary and autoimmune 
conditions were excluded performing imaging 
procedures, laboratory tests and liver biopsies. 
These last were compatible with damage indu-
ced by drugs. The discontinuation of CM intake 
determined rapid recovery in patients and the 
level of liver enzymes returned normal in 2-6 
months. Unintentional re-exposure determined 
recurrence of hepatitis in one patient, this fact, 
is the most appropriate criterion for HILI cau-
sality assessment45. In conclusion, a great per-
centage of unsolved cases of hepatitis could be 
related to CM. Moreover, the manifestation of 
jaundice related to acute hepatitis was observed 
in a 42-year-old woman, several weeks after the 
consumption a herbal remedy containing CM 
and curcuma root, which she took for a skin 
illness46. In accordance with the cases repor-
ted above, clinical conditions improved rapidly 
after the discontinuation of the herbal product 
and the hepatic functions were found to be nor-
mal within two months. Two cases of acute liver 
damage connected with the use of CM where 
also reported in 200347. In both patients, other 
culprits of acute liver injury were excluded, in 
order to assess causality. A recurrence of chole-
static hepatitis after CM re-exposure occurred 
in one patient. The two patients recovered fully, 
but the authors highlight the fact that the autho-
rization of CM administration should be recon-
sidered, as actually there is a lack of therapeutic 
benefits connected with this drug. Another case 
regards a 58-year-old man admitted with acute 
cholestatic hepatitis after the use of a CM pre-
paration48. Histopathology showed a picture of 
drug-induced hepatitis however after disconti-
nuation of the herbal product the patient recove-
red fully. A further case of liver damage was de-
scribed in 2008, involving a woman admitted to 
the hospital for asthenia, nausea, anorexia and 
with deranged liver enzymes49. She was found 
to have used a Lycopodium similiaplex prepara-
tion (containing Lycopodium serratum and Che-
lidonium majus) for 8 weeks before the onset 
of symptoms. Liver biopsy was suggestive of a 
hypersensitivity reaction and concordantly with 
the other reports she fully recovered. Teschke et 
al10 evaluated the connection between CM inta-
ke and hepatotoxicity in 21 published case re-
ports, using a causality evaluation method spe-
cific for the liver, as a multitude of confounding 
variables might have misled causality. For this 
reason, all 21 cases were examined through the 
CIOMS scale, which considers: risk factors, the 
latency period, comedication and other alterna-
tive causes, the trend of ALT after drug with-
drawal. The results showed a high probability 
of causality in two cases out of 21. Probable in 
six cases. Lower causality levels were found in 
the remaining cases in which the causality was 
excluded for three patients and recognized as 
possible in 10 cases. Regarding the 8 probable 
events, hepatotoxicity due to CM embodies an 
idiosyncratic reaction of the metabolic kind, 
while immunologic or mandatory hepatotoxic 
characteristics are missing. Therefore, an ac-
curate search and identification of confounding 
variables should be performed while evaluating 
the cases, but there is striking evidence for HILI 
due to GC in the cases analyzed by the authors. 
Moreover, the same author evaluated 22 spon-
taneous cases from Germany attributing to 8 
events, a highly probable or probable causality 
assessment, with a predominance for the female 
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gender50. All patients recovered. Taken together, 
the above-reported case reports actually support 
the hepatotoxic potential of CM preparations.
Conclusions
An abundant number of herbal remedies has 
been suggested to be linked with the risk of li-
ver damage, this side effect, as well as others, 
must be clearly underlined, in the light of an 
increase of popularity of herbal preparations51. 
Moreover, the clinical effectiveness of these 
remedies is frequently only supposed and does 
not seem to counterbalance the potential risks. 
Although important evidence of hepatotoxicity 
in animal studies is still not well defined, CM 
extracts and constituents displayed alterations 
and inhibition of liver metabolism suggestive 
for hepatotoxic potential. Numerous reports 
have been published about hepatotoxicity cases 
following CM intake, and several of them have 
been reported to be connected with CM expo-
sure with probability or high probability. Liver 
histology, when available, showed: liver cell 
necrosis (single or confluent), inflammation and 
more seldom cholestasis and fibrosis52. CM he-
patotoxicity has been defined as a distinct form 
of HILI, due to an idiosyncratic reaction of the 
metabolic type. This fact has to be evaluated in 
relationship with the lack of substantial benefits 
due to the therapy with CM. For these reasons, 
currently, the risk to benefit ratio of the use of 
herbal products containing CM can be consi-
dered as negative, although the described he-
patotoxicity has generally manifested a benign 
course with the recovery of the patients after 
discontinuation of the intake. 
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